TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics Statistics

Total Valuation

TCRX has a market cap or net worth of $77.53 million. The enterprise value is -$82.78 million.

Market Cap	77.53M
Enterprise Value	-82.78M

Important Dates

The last earnings date was Tuesday, May 6, 2025, before market open.

Earnings Date	May 6, 2025
Ex-Dividend Date	n/a

Share Statistics

TCRX has 56.59 million shares outstanding. The number of shares has increased by 18.13% in one year.

Current Share Class	52.31M
Shares Outstanding	56.59M
Shares Change (YoY)	+18.13%
Shares Change (QoQ)	+129.15%
Owned by Insiders (%)	0.76%
Owned by Institutions (%)	50.16%
Float	37.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	16.26
Forward PS	18.43
PB Ratio	0.34
P/TBV Ratio	0.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.55, with a Debt / Equity ratio of 0.46.

Current Ratio	8.55
Quick Ratio	8.44
Debt / Equity	0.46
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-41.42

Financial Efficiency

Return on equity (ROE) is -78.93% and return on invested capital (ROIC) is -33.45%.

Return on Equity (ROE)	-78.93%
Return on Assets (ROA)	-30.45%
Return on Invested Capital (ROIC)	-33.45%
Return on Capital Employed (ROCE)	-46.12%
Revenue Per Employee	$22,672
Profits Per Employee	-$674,277
Employee Count	195
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -82.28% in the last 52 weeks. The beta is 1.06, so TCRX's price volatility has been similar to the market average.

Beta (5Y)	1.06
52-Week Price Change	-82.28%
50-Day Moving Average	1.52
200-Day Moving Average	3.67
Relative Strength Index (RSI)	44.30
Average Volume (20 Days)	395,966

Short Selling Information

The latest short interest is 1.79 million, so 3.17% of the outstanding shares have been sold short.

Short Interest	1.79M
Short Previous Month	1.82M
Short % of Shares Out	3.17%
Short % of Float	4.83%
Short Ratio (days to cover)	3.46

Income Statement

In the last 12 months, TCRX had revenue of $4.42 million and -$131.48 million in losses. Loss per share was -$2.32.

Revenue	4.42M
Gross Profit	-5.36M
Operating Income	-139.70M
Pretax Income	-96.80M
Net Income	-131.48M
EBITDA	-136.17M
EBIT	-139.70M
Loss Per Share	-$2.32

Balance Sheet

The company has $251.69 million in cash and $97.04 million in debt, giving a net cash position of $154.65 million or $2.73 per share.

Cash & Cash Equivalents	251.69M
Total Debt	97.04M
Net Cash	154.65M
Net Cash Per Share	$2.73
Equity (Book Value)	210.20M
Book Value Per Share	3.71
Working Capital	225.02M

Cash Flow

In the last 12 months, operating cash flow was -$119.14 million and capital expenditures -$4.65 million, giving a free cash flow of -$123.79 million.

Operating Cash Flow	-119.14M
Capital Expenditures	-4.65M
Free Cash Flow	-123.79M
FCF Per Share	-$2.19

Margins

Gross Margin	-121.15%
Operating Margin	-3,159.87%
Pretax Margin	-2,974.08%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TCRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.13%
Shareholder Yield	-18.13%
Earnings Yield	-182.95%
FCF Yield	-172.25%

Analyst Forecast

The average price target for TCRX is $9.86, which is 619.71% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.86
Price Target Difference	619.71%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	121.82%
EPS Growth Forecast (5Y)	-35.07%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TCRX has an Altman Z-Score of -0.94 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.94
Piotroski F-Score	2